PECULARITIES OF CARBOHYDRARE METABOLISM IN PATIENTS WITH PROLACTINOMAS DURING SUPRESSIVE AGONIST DOPAMINE’S THERAPY

Authors

  • Khyzhnyak O.O. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv
  • Gogitidze T.G. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2015.3.09

Keywords:

prolactin, carbohydrate metabolism, insulin resistance, insulin sensitivity

Abstract

The article presents data of carbohydrate metabolism at the stages of long-term (12months) suppressive therapy dopamine agonist cabergoline in 61 patients with prolactinomas. It was proved that the normalization of prolactin levels during therapy reduces fasting glucose, HbA1c of patients, independently of gender. Insulin levels become normal in men with prior hyperinsulinemia and overweight. Pharmacology-induced hypoprolaktinemya not lead to disorders of carbohydrate metabolism.

References

Bole-Feysot C, Goffin V, Edery M, et al. Endocr Rev 1998; 19:225-268.

Beckers A, Adam C, Ciccarelli A, et al. ENEA abstr. Congress, Sorrento 2004: 23.

Yavuz D, Deyneli O, Akpınar I, et al. Eur J Endocrinology 2003; 149:187-193.

Osipova AA, Smetnik VP. Problemy Reprodukcii 2002; 1:12-17.

Dos Santos Silva CM, et al. Obesity 2011; 19(4):800-805.

Berinder K, Nystrôm T, Hôybye C, et al. Pituitary 2011; 14(3):199-207.

Tuzcu A, Bahceci M, Dursun M, et al. J Endocrinol Invest 2003; 26(4):341-346.

Goffin V, Bernichtein S, Touraine P, Kelly PA. Endocr Rev 2005; 26:400-422.

Bondarenko LI, Ivashhenko EV. Zdorov’e Zhenshhiny 2005; 1:121-126.

Masami O, Nobuhiro M, Kosaku A,et al. J Clin Endocrinol Metab 2010; 95(6):2672-2679.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(1):S.64-S.71.

The Oxford Centre for Diabetes, Endocrinilogy and Metabolism. HOMA Calculator, available at: http://www.dtu.ox.ac.uk.

Serri O, Li L, Mamputu JC, et al. Clin Endocrinol (Oxf.) 2006; 64:366-370.

Jiang XB, Li LC, He DS, et al. Pituitary 2014; 17:232-239.

Jiang XB, He DS, Mao ZG, et al. Tumour Biol 2013; 34:1171-1176.

DeFronzo RA. Diabetes Care 2011; 34:789-794.

Pijl H, Ohashi S, Matsuda M, et al. Diabetes Care 2000; 23:1154-1161.

Ciresi A, Amato MC, Guarnotta V, et al. Clin Endocrinol (Oxf.) 2013; 79:845-852.

Downloads

Published

2021-08-17

How to Cite

Кhyzhnyak O. O. ., & Gogitidze, T. G. . (2021). PECULARITIES OF CARBOHYDRARE METABOLISM IN PATIENTS WITH PROLACTINOMAS DURING SUPRESSIVE AGONIST DOPAMINE’S THERAPY. Problems of Endocrine Pathology, 53(3), 67-76. https://doi.org/10.21856/j-PEP.2015.3.09

Issue

Section

CLINICAL ENDOCRINOLOGY